October 16, 2026
Analyst Bio:
IMAX (NYSE:IMAX)'s stock had its "buy" rating restated by equities research analysts at Rosenblatt Securities in a report issued on Wednesday, Benzinga reports. They currently have a $65.00 target price on the stock. Rosenblatt Securities' price objective would indicate a potential upside of 27.75% from the company's current price.


